AssayIndex

AX-2026-042352

TB-500 · 2 mg declared · Hubei Jianxiang Bioscience Co., Ltd. · lot HJ-2511-L4170

MARGINALVERIFIED
Report ID
AX-2026-042352
Compound
TB-500
Compound class
Tissue-repair and immunomodulatory peptides
Supplier
HJ — Hubei Jianxiang Bioscience Co., Ltd.
Batch / lot
HJ-2511-L4170
Declared label claim
2mg
Laboratory
Janoshik Analytical
Assay date
21 Jun 2026
Submitted
07 Jul 2026
Quarter
2026-Q2
Submitter
v.yildiz
Sample provenance
Supplier-supplied
Section 1

Results

Measured against the index acceptance specification for the tissue-repair and immunomodulatory peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

ParameterMethodResultUnitIndex spec
PurityRP-HPLC, 30 min gradient, 214 nm99.93% area≥ 98.5PASS
Total impuritiesRP-HPLC, sum of reported peaks0.07% area≤ 1.5PASS
Largest single impurityRP-HPLC — C-terminal amide (−1 Da)0.04% area≤ 1.00PASS
Identity — theoretical monoisotopic masscalculated from molecular formula887.4964DaNOT TESTED
Identity — observed monoisotopic massLC-MS, high resolution (ESI-TOF/QTOF)887.5002DaNOT TESTED
Mass accuracyobserved vs theoretical+4.3ppm± 15PASS
Total peptide contentby difference from the gravimetric mass balance91.55%w/wNOT TESTED
Target-compound contenttotal peptide content × purity91.49%w/wNOT TESTED
Gross fill (as weighed)five-place balance, under nitrogen2.20mg2 mg declaredNOT TESTED
Recovered target peptidegross fill × target content2.013mg2 mg claimNOT TESTED
Recovery against label claimrecovered ÷ claim100.6%90.0 – 110.0PASS
Water contentKarl Fischer, coulometric, duplicate2.64%≤ 10.0PASS
Counter-ion (acetate)anion-exchange ion chromatography5.40%≤ 12.0PASS
Residual solvent + inorganic residueestimated — see /methods/residual-solvents-q3c/0.41%NOT TESTED
Endotoxinkinetic chromogenic LAL1.62EU/mg≤ 5.0PASS
Sterilitynot ordered on this submissionnot determinedno growthNOT TESTED
Appearancevisual, diffuse light, black and white backgroundWhite lyophilised cake, intactwhite to off-white intact cakePASS
Reconstitution clarityreconstituted per submitter procedureClear, colourless, no visible particulatesclear, no visible particulatesPASS
pH (reconstituted, 1 mg/mL)potentiometric, two-point calibration5.152.5 – 8.0PASS
Retention time (observed)RP-HPLC, 30 min gradient7.94min7.86 ± 0.25 (normalised)PASS
Peak asymmetry (10 % height)Ph. Eur. 2.2.460.970.80 – 1.50PASS
Plate count, main peakN = 5.54 (t/w½)²56,278≥ 20,000PASS
Resolution to nearest impurityvs [D-Thr]-diastereomer0.80no index criterionREPORTED
Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

0350970181052614035 TB-5007.94 min · 99.93 % 8.12 same trace · ×200 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 05101520253035 Retention time (min) Response (mAU)
Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 56,278, and skew follows the reported asymmetry factor of 0.97. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.04 % impurity against a 99.93 % main peak is a line two pixels tall; the main peak runs off-scale there by design.
#PeakRTArea (µV·s)% areaΔ mass (Da)
1TB-500 — main peak7.944,856,90899.93
2C-terminal amide (−1 Da)8.121,9440.04-0.984
3[D-Thr]-diastereomer7.831,4580.030.000
Closure check — purity + Σ impurities 100.00CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 887.4964 Da, computed from C39H69N9O14. All ppm figures on this site are against monoisotopic values — see why that matters.

0255075100375475575675775875975 [M+1H]1+888.51[M+2H]2+444.76 m/z Relative abundance (%)
Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 887.5002 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.
ChargeTheoretical m/zObserved m/zΔ m/zRel. abundance (%)
2+444.7555444.75740.001955.8
1+888.5037888.50750.0038100.0
Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

ComponentDetermination%w/w of cake
WaterKarl Fischer2.64
Counter-ion (acetate)ion chromatography5.40
Residual solvent + inorganic residueestimated0.41
Total peptide contentby difference91.55
Total100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

FigureSupplier COAThis reportIndex note
Purity (% area)99.9099.93divergence +0.09 pp vs batch median
Total impurities (% area)not stated0.07
Largest single impurity (% area)not stated0.04
Water (%)2.52.64
Counter-ion (%)9.25.40
Peptide content (%w/w)87.791.55
Endotoxin (EU/mg)not stated1.62
Method stated on certificateYEScolumn, gradient and wavelength given
Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance
Supplier-supplied
Evidentiary weight
Weaker evidence. Read with the caveat below.
Chain of custody
Supplier despatch → laboratory direct (courier, cold pack, 4 d) → assay. Submitter did not handle the vial.
Assay date
21 Jun 2026
Submitted to the index
07 Jul 2026
Laboratory
Janoshik Analytical, Ostrava, Czechia
Method basis
30 min gradient · high-resolution MS
Verification status
VERIFIED
Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot HJ-2511-L4170 n=3

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-042350HJ-2511-L4170Medutest2026-Q299.712.9196.7Supplier-supplied1MARGINAL
AX-2026-042351HJ-2511-L4170Nordanalyt2026-Q299.812.23Supplier-supplied1MARGINAL
Other recent TB-500 records in the index.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041847JEEPJEEP-2602-V3434Nordanalyt2026-Q399.723.85Supplier-supplied1MARGINAL
AX-2026-042574ERPERP-2605-S8022VendorInvestigate2026-Q399.542.9196.4Buyer-sourced1MARGINAL
AX-2026-042577ERPERP-2605-S8022Janoshik2026-Q399.513.45Supplier-supplied1MARGINAL
AX-2026-041845JEEPJEEP-2602-V3434Janoshik2026-Q399.724.04102.2Supplier-supplied1MARGINAL
AX-2026-041921JEEPJEEP-2605-M4874Janoshik2026-Q399.901.76Supplier-supplied2MARGINAL
AX-2026-041922JEEPJEEP-2605-M4874Janoshik2026-Q399.412.6095.7Laboratory-retained2MARGINAL
AX-2026-041928JEEPJEEP-2605-M4874Janoshik2026-Q399.881.8492.8Laboratory-retained2MARGINAL
AX-2026-041849JEEPJEEP-2602-V3434VendorInvestigate2026-Q399.733.6088.6Buyer-sourced2MARGINAL
Other recent HJ records in the index.
ReportCompoundLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-042368SemaxHJ-2603-V4363Nordanalyt2026-Q399.177.26106.3Supplier-supplied1MARGINAL
AX-2026-042347SemaglutideHJ-2608-C3931VendorInvestigate2026-Q398.803.41100.2Buyer-sourced1MARGINAL
AX-2026-042367SemaxHJ-2603-V4363Kestrel2026-Q399.106.7893.9Supplier-supplied1MARGINAL
AX-2026-042348SemaglutideHJ-2608-C3931Nordanalyt2026-Q399.524.19Supplier-supplied1MARGINAL
AX-2026-042290GHRP-6HJ-2603-R2258Janoshik2026-Q399.713.05Supplier-supplied2MARGINAL
AX-2026-042287GHRP-6HJ-2603-R2258VendorInvestigate2026-Q398.792.4390.9Buyer-sourced2FAIL
AX-2026-042288GHRP-6HJ-2603-R2258Kestrel2026-Q399.932.8292.8Supplier-supplied2MARGINAL
AX-2026-042346SemaglutideHJ-2608-C3931VendorInvestigate2026-Q399.403.48Buyer-sourced1MARGINAL